Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam for Neuropathic Pain in Chronic SCI
NCT05639946Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brivaracetam in neuropathic pain (2 arms), sponsored by University of Minnesota. Primary endpoints: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity at 7 weeks, The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Composite Neuropathic Pain at 7 weeks and 7 more. Started Jan 2023; status: completed.
02
Drugs
brivaracetam
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05639946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639946.